Citations

Clear

590 citation(s) found for "Ho, Ben".

An open invitation to join the Pediatric Proton/Photon Consortium Registry to standardize data collection in pediatric radiation oncology
Lawell, Miranda P. , Indelicato, Daniel J. , Hartsell, William F. , Perentesis, John P. , Vatner, Ralph E. , Perkins, Stephanie M., Mangona, V.S. , Hill‐Kayser, Christine E. , Kwok, Young , Chang, John, Wilkinson, J. Ben, MacEwan, Iain, Eaton, Bree R. , Gallotto, Sara L. , Weyman, Elizabeth A. , Bajaj, B., Baliga, Sujith , Yeap, Beow Y., González, Amy Berrington de , Yock, Torunn I. , Berrington de Gonzalez, Amy , Paulino, Arnold C. , Laack, Nadia N. , Ermoian, Ralph P. , Wolden, Suzanne L. , Chang, Andrew L., Ladra, Matthew M. , Indelicato, Daniel J , Yeap, Beow Y

Mayo Clinic

The British Journal of Radiology | October 10, 2019 | Volume: 93 | Issue: 1107 | Pages: No page available

10.1259/bjr.20190673 | PMID 31600082 Get It

Objective: The Pediatric Proton/Photon Consortium Registry (PPCR) is a comprehensive data registry composed of pediatric patients treated with radiation. It was established to expedite outcomes-based research. The attributes which allow the PPCR to be a successful collaboration are reviewed. Methods and materials: Current eligibility criteria are radiotherapy patients < 22 years treated at one of the 15 US participating institutions. Detailed health and treatment data are collected about the disease presentation and treatment exposures, and annually thereafter, in REDCap (Research Electronic Data Capture). DICOM (Digital Imaging and Communications in Medicine) imaging and radiation plans are collected through MIM/MIMcloud. An optional patient-reported quality-of-life (PedsQL) study is administered at 10 sites. Results: Accrual started October 2012 with 2,775 participants enrolled as of 25 July 2019. Most patients, 62.0%, were treated for central nervous system (CNS) tumors, the most common of which are medulloblastoma (n = 349), ependymoma (n = 309), and glial/astrocytoma tumors (n = 279). The most common non-CNS diagnoses are rhabdomyosarcoma (n = 284), Ewing’s sarcoma (n = 153), and neuroblastoma (n = 130). While the majority of participants are US residents, 18.7% come from 36 other countries. Over 685 patients participate in the PedsQL study. Conclusions: The PPCR is a valuable research platform capable of answering countless research questions that will ultimately improve patient care. Centers outside of the USA are invited to participate directly or may engage with the PPCR to align data collection strategies to facilitate large-scale international research. Advances in knowledge: For investigators looking to carry out research in a large pediatric oncology cohort or interested in registry work, this paper provides an updated overview of the PPCR.
Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)
Mandrekar, Sumithra J. , Laumann, Kristina, Sanford, Ben L. , Marcucci, Guido , Zhao, Weiqiang , Baer, Maria R. , Powell, Bayard L., Westervelt, Peter, Bloomfield, Clara D. , Byrd, John C. , Stone, Richard M. , Uy, Geoffrey L. , Levis, Mark J. , Klepin, Heidi D. , DeAngelo, Daniel J. , Stock, Wendy , Larson, Richard A.

Mayo Clinic

Blood | October 10, 2019 | Volume: 126 | Issue: 23 | Pages: 319-319

10.1182/blood.v126.23.319.319 Get It

Abstract Sorafenib is an oral multikinase inhibitor that blocks the autophosphorylation and activation of a number of kinases including the FLT3 tyrosine kinase with an internal tandem duplication mutation (FLT3-ITD). Sorafenib has activity against AML with FLT3-ITD mutations as a single agent in the setting of post-transplant relapse and in combination with chemotherapy for newly diagnosed AML. Historical Cancer and Leukemia Group B results using standard chemotherapy for older patients (pts) with FLT3-ITD have demonstrated a complete remission (CR) rate of 67%, median survival of 0.8 yrs, and 1-yr overall survival (OS) of 30% (Whitman et al., Blood 2010). More recently, sorafenib was demonstrated to significantly prolong event-free (EFS) and disease-free survival (DFS) of younger adults irrespective of FLT3 mutation status (Rollig, et al., ASH 2014). We hypothesized that the addition of sorafenib to induction and post-remission therapy would improve the overall survival of older pts with FLT3-mutated AML. The Alliance for Clinical Trials in Oncology conducted a multicenter, single-arm phase 2 study in pts ≥ 60 years old with AML and either a FLT3-ITD or a point mutation in the activation loop of the kinase domain (FLT3-TKD). Subjects with PML-RARA, core-binding factor AML or who had received prior treatment for AML were excluded. Induction chemotherapy consisted of cytarabine 100 mg/m2 CIVI on days 1-7 and daunorubicin 60 mg/m2 IV on days 1-3 (7+3) with oral sorafenib 400 mg bid on days 1-7. Those not achieving a hypoplastic bone marrow on day 14 were to receive a second cycle of cytarabine and daunorubicin (5+2) plus sorafenib 400 mg bid on days 1-7. Post-remission therapy consisted of intermediate-dose cytarabine 2 g/m2 on days 1-5 with sorafenib 400 mg bid on days 1-28 for 2 cycles followed by maintenance sorafenib 400 mg bid for 12 28-day cycles. The primary endpoint of the study was 1-yr OS. With a sample size of 39 FLT3-ITD patients and type I error rate of 10%, this design provided 90% power to distinguish between true 1-yr OS rate of 50% compared to our historical rate of 30% for the FLT3-ITD pts. A total of 474 pts were screened for FLT3 mutations though a central laboratory. FLT3 mutations were identified in 83 subjects (17.5%). Fifty-four pts with a median age of 67 years (60.3-82.7) were enrolled, including 39 with FLT3-ITD (71%) and 15 with FLT3-TKD (29%). All pts have now completed protocol treatment. Of the 54 pts, 37 achieved a CR or CRi (69%). The 30-day induction mortality was 9% with no additional deaths occurring between days 30-60. With a median follow up of 28.3 months, the observed 1-yr OS (95% CI) was 62% (45-78) for the FLT3-ITD pts and 71% (42-92) for the FLT3-TKD pts. The median DFS and OS was 12.5 mo (7.7-17.4) and 15.0 mo (10.4-20.1) respectively in the FLT3-ITD group and 9.0 (1.6-NA) and 16.2 mo (5.0-NA) for the FLT3-TKD group. For all subjects, the 2-yr OS was 28% (17-43) and DFS was 27% (15-46). There were no treatment-related deaths during consolidation or maintenance. For pts receiving sorafenib maintenance, the most commonly reported related adverse events were Grade 1 diarrhea, fatigue, transaminitis, and Grade 2 palmar-plantar erythodyesthesia. The mean plasma inhibitory activity (PIA) for FLT3 was 94% (n=25) on day 6 of induction, 93% (n=15) on day 15 of consolidation and 99.2% (n=6) on day 15 of maintenance demonstrating robust inhibition of FLT3 in vivo. This study represents the first prospective clinical trial for older adults with AML targeting a specific mutational profile within the US cooperative group setting. The study met the primary endpoint demonstrating that the addition of sorafenib to chemotherapy for FLT3-ITD AML improves the survival of older adults more than doubling the 1-yr OS compared to historical controls (62% vs 30%, p <0.0001). Disclosures Uy: Novartis: Research Funding. Off Label Use: Sorafenib for AML. DeAngelo:Novartis: Consultancy; Ariad: Consultancy; Bristol Myers Squibb: Consultancy; Pfizer: Consultancy; Amgen: Consultancy; Incyte: Consultancy; Agios: Consultancy; Celgene: Consultancy. Stock:Gilead: Membership on an entity's Board of Directors or advisory committees. Byrd:Acerta Pharma BV: Research Funding. Stone:Celator: Consultancy; Celgene: Consultancy; Pfizer: Consultancy; Roche/Genetech: Consultancy; Amgen: Consultancy; Karyopharm: Consultancy; Abbvie: Consultancy; AROG: Consultancy; Merck: Consultancy; Sunesis: Consultancy, Other: DSMB for clinical trial; Novartis: Research Funding; Juno: Consultancy; Agios: Consultancy. Larson:Bristol-Myers Squibb: Consultancy; Pfizer: Consultancy; Ariad: Consultancy, Research Funding; Novartis: Consultancy, Research Funding.
Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML
Bartholdy, Boris , Zhou, Li , Todorova, Tihomira I. , Stanley, Robert , Paietta, Elisabeth , Cripe, Larry D., Fernández, Hugo F. , Greenberg, Peter L. , Rowe, Jacob M. , Tallman, Martin S. , Mitsiades, Constantine S. , Verma, Amit , Steidl, Ulrich , Barreyro, Laura , Will, Britta , Ben‐Neriah, Susana , Montagna, Cristina , Parekh, Samir , Pellagatti, Andrea , Boultwood, Jacqueline , Ketterling, Rhett P. , Steidl, Christian

Mayo Clinic

Blood | October 10, 2019 | Volume: 120 | Issue: 21 | Pages: 1875-1875

10.1182/blood.v120.21.1875.1875 Get It

Abstract Abstract 1875 Recent experimental evidence suggests that acute myeloid leukemia (AML) originates from hematopoietic stem and progenitor cells (HSPC) following the acquisition of multiple genetic or epigenetic changes that initially give rise to pre-leukemic HSPC (pre-LSC) and then to fully transformed leukemia stem cells (LSC). Relapse continues to be the major cause of death in most subtypes of AML, suggesting that current therapies are largely ineffective in eliminating LSC and pre-LSC. Cellular heterogeneity and the recent observation that LSC are contained within different phenotypic cellular compartments are challenges for the identification of pathways contributing to the initiation and maintenance of AML. To address these challenges we employed a novel strategy of parallel transcriptional analysis of multiple phenotypic HSPC populations from individuals with AML with normal karyotype (N=5), -7/7q- (N=6) and complex karyotype (N=5), including long-term HSC, short-term HSC, and granulocyte-monocyte progenitors (GMP), and comparison to corresponding cell populations from age-matched healthy controls (HC) (N=6). Specifically, we sorted Lin−/CD34+/CD38−/CD90+ (LT-HSC), Lin−/CD34+/CD38−/CD90− (ST-HSC), and Lin−/CD34+/CD38+/CD123+/CD45RA+ (GMP), and hybridized RNA to Affymetrix GeneST 1.0 expression arrays. Differential gene expression was determined within each compartment by direct comparison of AML LT-HSC vs. HC LT-HSC, AML ST-HSC vs. HC ST-HSC, and AML GMP vs. HC GMP. Subsequent intersection of all differentially expressed genes revealed that only a relatively small number of 6 to 11 genes were consistently dysregulated in all examined leukemic stem and progenitor cell compartments. Interleukin 1 receptor accessory protein (IL1RAP) was one of the most significantly upregulated genes in LT-HSC, ST-HSC, and GMP in all examined subtypes of AML. IL1RAP is a transmembrane protein required for signaling through several receptors of the IL1 family, including IL-1R1 and ST2. We detected significant overexpression of IL1RAP protein on HSC and progenitor cells of AML patients. Interestingly, CD34+/Lin+ precursor cells showed only a marginal increase of IL1RAP at the protein level in AML, underscoring the importance of purifying HSPC with stringent lineage depletion. We performed fluorescence in situ hybridization in sorted IL1RAP+ and IL1RAP− cells from -7 AML. We observed that the -7 clone was restricted to IL1RAP+ cells, while IL1RAP- cells did not display monosomy 7, demonstrating that IL1RAP overexpression is a distinguishing feature of the cells of the -7 clone. Patients with normal karyotype AML showed a wider range of IL1RAP expression levels; some were as high as in -7 AML and others were as low as in HC. We asked whether IL1RAP expression levels were associated with known clinical or molecular parameters. We analyzed two published datasets of patients with normal karyotype AML (Metzeler, Blood. 2008;112:4193–4201; Tomasson, Blood. 2008;111:4797–4808). Patients with high IL1RAP levels showed inferior overall survival than patients with lower IL1RAP (p=2.2×10−7; median survival: 7.82 mo. for IL1RAP high, 20 mo. for IL1RAP low). Multivariate analysis using a Cox regression model showed that high IL1RAP status was an independent prognostic factor (p=0.002), and even stronger than FLT3 mutation status (p=0.006). In addition, we analyzed data from 183 patients with MDS and found IL1RAP expression to be specifically elevated in cases with RAEB-2, suggesting a role of IL1RAP in MDS and in the progression to AML. Downregulation of IL1RAP protein expression in 4 AML cell lines (THP1, OCI-AML3, HL60, HEL) led to a significant 45–98% decrease in clonogenic growth and increased apoptosis in vitro. To assess the effects of IL1RAP downregulation in vivo, we performed xenotransplants into immunodeficient NOD/SCID/IL2Rg-null mice. THP-1 AML cells showed a 92% reduced proliferation and infiltration of hematopoietic organs upon IL1RAP knockdown in comparison to a non-silencing control in vivo. Genetic studies to assess the role of IL1RAP in the initiation and maintenance of AML in an IL1RAP−/− mouse model are currently ongoing. In summary, our study provides a map of consistently dysregulated transcripts across multiple fractionated stem and progenitor cell types from patients with AML, and identifies IL1RAP as a putative new therapeutic and prognostic target in stem cells in AML and MDS. Disclosures: No relevant conflicts of interest to declare.
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
Fitzmaurice, Christina , Abate, Degu , Abbasi, Naghmeh , Abbastabar, Hedayat , Abdelalim, Ahmed , Abdoli, Amir , Abdulle, Abdishakur S. M., Abebe, Nebiyu Dereje , Abraha, Haftom Niguse , Abualhasan, Ahmed , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Afarideh, Mohsen , Afshari, Mahdi , Aghaali, Mohammad , Agius, Dominic, Agrawal, Sutapa , Ahmadi, Ayat , Ahmed, Muktar Beshir , Akbari, Mohammad Esmaeil , AlAbdulKader, Assim M. , Alahdab, Fares , Alam, Shazia , Alamene, Genet Melak, Alene, Kefyalew Addis , Alipour, Vahid, Bakeshei, Fatemeh Allah, Almadi, Majid A. , Alsharif, Ubai , Alsowaidi, Shirina, Alvis‐Guzmán, Nelson , Amini, Saeed, Anbari, Zohreh , Anber, Nahla , Andrei, Cătălina Liliana , Anjomshoa, Mina, Ansari, Fereshteh, Ansariadi, Ansariadi , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Areri, Habtamu Abera , Artaman, Al, Asfaw, Ephrem Tsegay, Ashagre, Alebachew Fasil, Assadi, Reza , Atalay, Hagos Tasew , Ataro, Zerihun , Atique, Suleman , Ávila‐Burgos, Leticia , Avokpaho, Euripide , Awasthi, Ashish , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayanore, Martin Amogre , Ayele, Henok Tadesse, Babaee, Ebrahim , Bacha, Umar, Badawi, Alaa, Bagherzadeh, Mojtaba , Bagli, Eleni , Balakrishnan, Senthilkumar , Bärnighausen, Till , Battista, Robert J., Behzadifar, Meysam, Belay, Yared Belete , Berfield, Kathleen, Berhane, Adugnaw , Bernabé, Eduardo , Beuran, Mircea , Bhakta, Nickhill , Bhattacharyya, Krittika , Biadgo, Belete , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Bisignano, Catherine, Bitew, Helen , Bjørge, Tone , Bogale, Kassawmar Angaw , Bojia, Hunduma Amensisa, Borzì, Antonio Maria , Bou-Orm, Ibrahim R. , Brenner, Hermann , Brewer, Jerry D., Briko, Andrey , Брико, Н. И. , Bustamante-Teixeira, Maria Teresa , Butt, Zahid A , Carreras, Giulia , Carvalho, Félix , Castro, Clara , Castro, Franz , Catalá-López, Ferrán , Cerin, Ester , Chaiah, Yazan , Chanie, Wagaye Fentahun, Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chauhan, Neelima Singh, Chiang, Peggy Pei-Chia, Chichiabellu, Tesfaye Yitna , Chido‐Amajuoyi, Onyema Greg , Chimed‐Ochir, Odgerel , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Crowe, Christopher S. , Curado, María Paula , Dahlawi, Saad M A , Damiani, Giovanni , Darwish, Amira Hamed , Demissie, Birhanu Wondimeneh , Demoz, Gebre Teklemariam , Derakhshani, Afshin , Deribe, Kalkidan Solomon, Desai, Rupak , Desalegn, Beruk Berhanu , Dey, Subhojit , Dhimal, Meghnath , Díaz, Daniel , Dinberu, Mesfin Tadese, Djalalinia, Shirin, Drake, Thomas M , Dubljanin, Eleonora , Duken, Eyasu Ejeta, Effiong, Andem , Eftekhari, Aziz , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Elemineh, Demelash Abewa , Elkout, Hajer , Ellenbogen, Richard G. , Elsharkawy, Aisha , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Endries, Aman Yesuf , Eshrati, Babak, Fadhil, Ibtihal , Farzadfar, Farshad , Fentahun, Netsanet , Fernandes, Eduarda , Feyissa, Garumma Tolu , Fischer, Florian , Fisher, James L. , Force, Lisa M , Freitas, Marisa , Fukumoto, Takeshi , Futran, Neal D. , Gallus, Silvano , Gankpé, Fortuné Gbètoho , Gayesa, Reta Tsegaye, Gebrehiwot, Tsegaye Tewelde , Gebremeskel, Gebreamlak Gebremedhn , Gedefaw, Getnet , Gelaw, Belayneh K., Geta, Birhanu, Getachew, Sefonias , Gezae, Kebede Embaye , Ghafourifard, Mansour , Ghajar, Alireza , Ghashghaee, Ahmad , Gholamian, Asadollah , Ginindza, Themba G. , Girmay, Alem, Gizaw, Muluken , Gomez, Ricardo Santiago , Gopalani, Sameer Vali , Gorini, Giuseppe , Goulart, Bárbara Niegia Garcia de , Grada, Ayman , Guerra, Maximiliano Ribeiro, Guimarães, André Luiz Sena , Gupta, Prakash C. , Hadkhale, Kishor , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hamidi, Samer , Hanfore, Lolemo Kelbiso , Hasankhani, Milad , Hasanzadeh, Amir , Hassen, Hamid Yimam , Hay, Simon I , Henok, Andualem , Herţeliu, Claudiu , Hoang, Chi Linh , Hole, Michael K., Hoogar, Praveen , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela, Hostiuc, Sorin , Househ, Mowafa , Hussen, Mohammedaman Mama, Ileanu, Bogdan Vasile , Ilić, Milena , Innos, Kaire , Irvani, Seyed Sina Naghibi , Iseh, Kufre Robert , Islam, Sheikh Mohammed Shariful , Balalami, Nader Jafari, Jafarinia, Morteza , Jahangiry, Leila , Jahanmehr, Nader , Jakovljević, Mihajlo, James, Spencer L , Jayaraman, Sudha , Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Jürisson, Mikk , Kamangar, Farin , Karimi, Narges , Karimian, Ansar , Kasaeian, Amir , Kasahun, Gebremicheal Gebreslassie , Kassa, Belete, Kassaw, Mesfin Wudu , Kaul, Anil, Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khalilarjmandi, Maryam, Khan, Ejaz Ahmad , Khan, Gulfaraz , Khang, Young-Ho, Khater, Amir M, Khayamzadeh, Maryam , Khazaee-Pool, Maryam , Khosravi, Mohammad Hossein , Khubchandani, Jagdish , Kianipour, Neda, Kim, Daniel , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Krohn, Kristopher J, Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kuupiel, Desmond , Lad, Deepesh , Lake, Eyasu Alem , Lakew, Ayenew Molla , Lal, Dharmesh Kumar, Lami, Faris , Lan, Qing , Lasrado, Savita , Lazarus, Jeffrey V. , Leigh, James , Leshargie, Cheru Tesema , Liao, Yu , Limenih, Miteku Andualem , Listl, Stefan , Lopukhov, Platon D , Lunevičius, Raimundas , Madadin, Mohammed , Razek, Hassan Magdy Abd El , Majeed, Azeem , Manafi, Ali, Manafi, Navid , Manamo, Wondimu Ayele, Mantovani, LG , Martini, Santi , Mashamba-Thompson, Tivani P. , Massenburg, Benjamin B. , Maswabi, Motswadi Titus, McAlinden, Colm , Meheretu, Hailemariam Abiy Alemu , Mehrotra, Ravi , Meles, Gebrekiros Gebremichael , Meles, Hagazi Gebre , Melku, Mulugeta , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Merat, Shahin , Meretoja, Tuomo J , Miazgowski, Bartosz , Miazgowski, Tomasz , Mihretie, Kebadnew Mulatu M., Miller, Ted R. , Mills, Edward J , Mir, Seyed Mostafa , Mishra, Rashmi , Moazen, Babak , Mohammad, Dara K., Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Moslem, Mohammadian, Mahdi , Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Ammas Siraj , Mohammed, Jemal , Mohammed, Shafiu , Mohebi, Farnam , Mokdad, Ali H. , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moossavi, Maryam , Moradi, Ghobad , Moradi-Joo, Mohammad , Moradpour, Farhad , Morawska, Lídia , Morgado-da-Costa, Joana, Mosapour, Abbas , Mousavi, Seyyed Meysam , Muche, Achenef Asmamaw , Muhammed, Oumer Sada , Musa, Jonah , Nabhan, Ashraf , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Nagel, Gabriele , Naik, Gurudatta , Nam, Hae‐Sung , Nazari, Javad , Negoi, Ionuţ , Neupane, Subas , Nggada, Haruna Asura , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikniaz, Leila , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Nixon, Molly R, Nnaji, Chukwudi A , Shiadeh, Malihe Nourollahpour , Obsa, Mohammed Suleiman , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olagunju, Tinuke O , Oluwasanu, Mojisola , Omonisi, Abidemi , Onwujekwe, Obinna , Oommen, Anu Mary , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakpour, Amir H. , Pană, Adrian , Park, Eun‐Kee , Patel, Shanti, Patil, Snehal T, Pennini, Alyssa, Piccinelli, Cristiano, Pillay, Julian David , Pirestani, Majid , Postma, Maarten J. , Pourmalek, Farshad , Pourshams, Akram , Prakash, Swayam , Rabiee, Navid , Radfar, Amir , Rafiei, Alireza , Rahim, Fakher , Rahimi, Mahdi , Rahman, Muhammad Aziz , Rajati, Fatemeh , Rana, Saleem M., Raoofi, Samira , Rath, Goura Kishor, Rawaf, David Laith , Reiner, Robert C. , Renzaho, André M. N. , Rezapour, Aziz, Ribeiro, Ana Isabel , Ribeiro, Daniela , Roro, Elias Merdassa , Rostami, Ali , Saad, Ragy , Sabbagh, Parisa , Saddik, Basema , Safiri, Saeid , Salahshoor, Mohammad Reza , Salehi, Farkhonde , Salem, Hosni , Salem, Marwa Rashad , Salimzadeh, Hamideh , Salomon, Joshua A. , Samy, Abdallah M , Sanabria, Juan , Santric-Milicevic, Milena M , Sartorius, Benn , Sarveazad, Arash , Sathian, Brijesh , Satpathy, Maheswar , Savic, Miloje , Sawhney, Monika, Seyedmousavi, Seyedmojtaba , Shaahmadi, Faramarz , Shabaninejad, Hosein , Shahbaz, Mohammad , Shaikh, Masood Ali, Shamshirian, Amir , Shamsizadeh, Morteza , Sharafi, Zeinab , Sharifi, Ali , Sharifi, Hamid , Shirkoohi, Reza , Shukla, Sharvari , Si, Si , Siabani, Soraya , Silva, Diego Augusto Santos , Singh, Ambrish , Sisay, Solomon , Sobngwi, Eugène , Soofi, Moslem , Soriano, Joan B. , Stathopoulou, Vasiliki, Sufiyan, Mu’awiyyah Babale , Tabarés‐Seisdedos, Rafael , Tabuchi, Takahiro , Takahashi, Ken , Tarawneh, Mohammed Rasoul , Tassew, Segen Gebremeskel , Taymoori, Parvaneh , Temsah, Mohamad‐Hani , Temsah, Omar, Tesfay, Fisaha Haile , Teshale, Manaye Yihune, Tessema, Gizachew Assefa , Thapa, Subash , Tlaye, Kenean Getaneh , Topór-Mądry, Roman , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Khanh Bao , Tsadik, Afewerki Gebremeskel , Ullah, Irfan , Vaezi, Maryam, Pérez, Patricia Varona , Vidale, Simone , Violante, Francesco Saverio , Vollset, Stein Emil, Vos, Theo , Vosoughi, Kia , Vu, Giang Thu , Vujcic, Isidora S , Wabinga, Henry, Wachamo, Tesfahun Mulatu , Wagnew, Fasil Shiferaw, Waheed, Yasir , Weldegebreal, Fitsum , Weldesamuel, Girmay Teklay, Wijeratne, Tissa , Wonde, Tewodros Eshete , Workie, Hailemariam Mekonnen , Yadav, Rajaram , Yadegar, Abbas , Yadollahpour, Ali , Yaseri, Mehdi , Yazdi‐Feyzabadi, Vahid , Yeshaneh, Alex , Yimam, Mohammed , Yisma, Engida , Younis, Mustafa Z , Zadnik, Vesna, Moghadam, Telma Zahirian , Zandian, Hamed , Zangeneh, Alireza , Zaki, Leila , Zendehdel, Kazem , Zenebe, Zerihun Menlkalew, Zewale, Taye Abuhay , Ziapour, Arash , Zodpey, Sanjay , Murray, Christopher J L , Topór‐Mądry, Roman , Deribe, Kebede , Teklay, Girmay , Wijeratne, T , Kumar, Vivek , Lazarus, Jeffrey V , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Abd-Allah, Foad , Abdel-Rahman, Omar Mohammed , Abdollahpour, Ibrahim , Abu-Raddad, Laith Jamal , Ahmadian, Elham , Ahmadpour, Ehsan , Akinyemiju, Tomi , Al‐Aly, Ziyad , Alemnew, Birhan , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Erfan , Amini, Saeed, Amoako, Yaw Ampem , Arab-Zozani, Morteza , Asayesh, Hamid , Fasil, Alebachew , Ataeinia, Bahar , Ausloos, Marcel , Balouchi, Abbas , Behzadifar, Masoud , Behzadifar, Meysam, Bekele, Bayu Begashaw , Belayneh, Yaschilal Muche , Birungi, Charles , Bleyer, Archie , Bosetti, Cristina , Carrero, Juan Jesús , Chaturvedi, Pankaj , Chehrazi, Mohammad , Constantin, María Magdalena , Crocetti, Emanuele , Daryani, Ahmad , Neves, José das , Demeke, Feleke Mekonnen , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Deribe, Kalkidan Solomon, Desta, Melaku , Dharmaratne, Samath Dhamminda , Doku, David Teye , Dubey, Manisha , Ebrahimi, Hedyeh , Sayed, Iman El , Zaki, Maysaa El Sayed , Adane, Daniel, Omrani, Vahid Fallah , Faramarzi, Mahbobeh , Farhangi, Mahdieh Abbasalizad , Farioli, Andrea , Filip, Irina , Foroutan, Masoud , Tsegaye, Reta , Gelaw, Belayneh K., Gill, Paramjit Singh , Gupta, Rahul, Haro, Josep María , Hay, Roderick J. , Henry, Nathaniel J , Hidru, Hagos Degefa , Horita, Nobuyuki , Hosgood, H. Dean, Hostiuc, Mihaela, Hussen, Mohammedaman Mama, Islami, Farhad , Jahani, Mohammad Ali , Jakovljević, Mihajlo , Javanbakht, Mehdi , Jee, Sun Ha , Jenabi, Ensiyeh , Jonnagaddala, Jitendra, Jungari, Suresh Banayya , Kabir, Ali , Karch, André , Kassa, Tesfaye , Kerbo, Amene Abebe , Khang, Young-Ho, Khatab, Khaled , Khazaei, Salman , Khoja, Abdullah T , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Vecchia, Carlo La , Lal, Dharmesh Kumar, Lauriola, Paolo , Lopez, Alan D , Magdeldin, Sameh , Maleki, Afshin , Malekzadeh, Reza , Manamo, Wondimu Ayele, Mansourian, Morteza , Mansournia, Mohammad Alì , Maroufizadeh, Saman , Mathur, Manu Raj , McKee, Martin , Mehta, Varshil , Meier, Toni , Melaku, Yohannes Adama , Melese, Addisu Dagnaw , Meštrović, Tomislav , Mulatu, Kebadnew , Mirzaei, Hamed , Mirzaei, Hamid Reza , Mohammad, Dara K., Darwesh, Aso Mohammad , Mohammadbeigi, Abolfazl , Mohammadi, Hiwa , Mohammadi, Moslem, Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Nahvijou, Azin , Najafi, Farid , Naldi, Luigi , Nasiri, Naser , Newcomb, Polly A. , Nojomi, Marzieh , Nosratnejad, Shirin , Oh, In‐Hwan , Oren, Eyal , Ota, Erika , Owolabi, Mayowa , Parsian, Hadi , Pashaei, Tahereh , Pereira, David M. , Pishgar, Farhad , Pourjafar, Hadi , Prasad, Narayan , Qorbani, Mostafa , Rabiee, Mohammad , Rana, Saleem M., Rawaf, Salman , Rezaei, Nima , Ronfani, Luca , Roshandel, Gholamreza , Saad, Ragy , Sabbagh, Parisa, Sabour, Siamak , Sahebkar, Amirhossein , Sayyah, Mehdi , Schneider, Ione Jayce Ceola , Schöttker, Ben , Šekerija, Mario , Sepanlou, Sadaf Ghajarieh , Sepehrimanesh, Masood , Sharafi, Heidar , Sharif, Mehdi , Sharma, Rajesh , Sheikh, Aziz , Silveira, Dayane Gabriele Alves , Singh, Jasvinder A. , Sitas, Freddy , Tamtaji, Omid Reza , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Teshale, Manaye Yihune, Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Vacante, Marco , Vaezi, Maryam, Veisani, Yousef , Vlassov, Vasily , Vollset, Stein Emil, Wagnew, Fasil , Wondafrash, Dawit Zewdu , Wondmieneh, Adam Belay , Yimer, Ebrahim M , Yonemoto, Naohiro , Yousefi, Bahman , Yousefifard, Mahmoud , Yu, Chuanhua , Zabeh, Erfan , Zaidi, Zoubida , Zamani, Mohammad , Olagunju, Andrew T , Bhakta, Nickhill , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

JAMA Oncology | September 27, 2019 | Volume: 5 | Issue: 12 | Pages: 1749

10.1001/jamaoncol.2019.2996 | PMID 31560378 Get It

The relationship between obstructive sleep apnoea and postoperative delirium and pain: an observational study of a surgical cohort
Strutz, Patricia , Tzeng, William S. , Arrington, Brianna, McKinnon, Sherry, Abdallah, Arbi Ben , Haroutounian, Simon , Kronzer, Vanessa L. , Avidan, Michael Simon

Mayo Clinic

Anaesthesia | September 18, 2019 | Volume: 74 | Issue: 12 | Pages: 1542-1550

10.1111/anae.14855 | PMID 31531850 Get It

Summary Patients with obstructive sleep apnoea are at increased risk of adverse postoperative outcomes, such as cardiac and respiratory complications. It has been hypothesised that obstructive sleep apnoea also increases the risk for postoperative delirium and acute postoperative pain. We conducted a retrospective, observational study investigating the relationship of obstructive sleep apnoea with postoperative delirium and acute postoperative pain severity. Patients were classified as being at high risk for obstructive sleep apnoea if they had been diagnosed with this condition, or if they were positive for more than four factors using the ‘ STOP ‐ BANG ’ screening tool. Adjusted logistic regression was used to investigate the association between obstructive sleep apnoea and postoperative delirium, and multivariable linear regression to study the relationship between obstructive sleep apnoea and postoperative pain severity. The incidence of postoperative delirium was 307 in 1441 patients (21.3%; 95% CI 19.2–23.5%). In unadjusted analysis, high risk for obstructive sleep apnoea was associated with delirium, with an odds ratio (95% CI ) of 1.77 (1.22–2.57; p = 0.003). After adjustment for pre‐specified variables, the association was not statistically significant with odds ratio 1.34 (0.80–2.23; p = 0.27). The mean ( SD ) maximum pain (resting or provoked) reported for the entire cohort was 63.8 (27.9) mm on a 0–100 mm visual analogue scale. High risk for obstructive sleep apnoea was not associated with postoperative pain severity (β‐coefficient 2.82; 95% CI , −2.34–7.97; p = 0.28). These findings suggest that obstructive sleep apnoea is unlikely to be a strong risk factor for postoperative delirium or acute postoperative pain severity.
Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism
Lindström, Sara , Wang, Lu , Smith, Erin N. , Gordon, William, Vlieg, Astrid van Hylckama , Andrade, Mariza de , Brody, Jennifer A. , Pattee, Jack , Haessler, Jeffrey, Brumpton, Ben , Suchon, Pierre , Chen, Ming‐Huei , Germain, Marine , Wiggins, Kerri L. , Brækkan, Sigrid K. , Armasu, Sebastian M. , Jackson, Rebecca D., Giulianini, Franco, Puurunen, Marja , Ibrahim, Manal , Heckbert, Susan R. , Natarajan, Pradeep , Klarin, Derek , Program, The Million Veteran, Vries, Paul S. de , Sabater‐Lleal, Maria , Group, The CHARGE Hemostasis Working, Bammler, Theo K. , Frazer, Kelly A. , McCauley, Bryan M. , Pankow, James S. , Reiner, Alex P. , Gabrielsen, Maiken E. , Kim, Jihye , McKnight, Barbara, Hansen, J.-B., Heit, John A. , Tang, Weihong , Morange, Pierre‐Emmanuel , Johnson, Andrew D. , Kabrhel, Christopher , Trégouët, David‐Alexandre , Smith, Nicholas L. , Assimes, Themistocles L. , Ballantyne, Christie M. , Hansen, John‐Bjarne , Frazer, Kelly A , de Andrade, Mariza , Assimes, Themistocles L , Wiggins, Kerri L , Ballantyne, Christie M , Natarajan, Pradeep , Braekkan, Sigrid K , Germain, Marine , Brumpton, Ben , Sabater-Lleal, Maria , Pankow, James S , Tang, Weihong , Brody, Jennifer A , Chasman, Daniel I. , Turman, Constance , MacDonald, James W. , Pankratz, Nathan , Nielsen, Jonas Bille , Damrauer, Scott M , Program, The Million Veteran, Huffman, Jennifer E. , Group, The CHARGE Hemostasis Working, Taylor, Kent D. , Deleuze, Jean‐François , O'Donnell, Chris J., Kraft, Peter , Rosendaal, Frits R , Psaty, Bruce M. , Kooperberg, Charles , Hveem, Kristian , Ridker, Paul M.

Mayo Clinic

Blood | August 16, 2019 | Volume: 134 | Issue: 19 | Pages: 1645-1657

10.1182/blood.2019000435 | PMID 31420334 Get It

In this work related to familial aggregation of familial venous thromboembolism, the investigators report genomic and transcriptomic association of 16 novel susceptibility loci for venous thromboembolism.
Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation
Alnsasra, Hilmi , Schettle, Sarah , Pereira, Naveen L. , Frantz, Robert P. , Edwards, Brooks S., Clavell, Alfredo L. , Maltais, Simon, Daly, Richard C. , Stulak, John M., Rosenbaum, Andrew , Behfar, Atta , Kushwaha, Sudhir S. , Asleh, Rabea , Schettle, Sarah D., Rosenbaum, Andrew N , Behfar, Atta , Frantz, Robert P

Mayo Clinic

Journal of the American Heart Association | August 14, 2019 | Volume: 8 | Issue: 16 | Pages: No page available

10.1161/jaha.119.012073 | PMID 31411097 Get It

Background Diastolic pulmonary gradient ( DPG ) was proposed as a better marker of pulmonary vascular remodeling compared with pulmonary vascular resistance ( PVR ) and transpulmonary gradient ( TPG ). The prognostic significance of DPG in patients requiring a left ventricular assist device ( LVAD ) remains unclear. We sought to investigate whether pre‐ LVAD DPG is a predictor of survival or right ventricular ( RV ) failure post‐ LVAD . Methods and Results We retrospectively reviewed 268 patients who underwent right heart catheterization before LVAD implantation from 2007 to 2017 and had pulmonary hypertension because of left heart disease. Patients were dichotomized using DPG ≥7 mm Hg, PVR ≥3 mm Hg, or TPG ≥12 mm Hg. The associations between these parameters and all‐cause mortality or RV failure post LVAD were assessed with Cox proportional hazards regression and Kaplan–Meier analyses. After a mean follow‐up time of 35 months, elevated DPG was associated with increased risk of RV failure (hazard ratio [ HR ]: 3.30; P =0.004, for DPG ≥7 versus DPG <7), whereas elevated PVR ( HR 1.85, P =0.13 for PVR ≥3 versus PVR <3) or TPG ( HR 1.47, P =0.35, for TPG ≥12 versus TPG <12) were not associated with the development of RV failure. Elevated DPG was not associated with mortality risk ( HR 1.16, P =0.54, for DPG ≥7 versus DPG <7), whereas elevated PVR , but not TPG , was associated with higher mortality risk ( HR 1.55; P =0.026, for PVR ≥3 versus PVR <3). Conclusions Among patients with pulmonary hypertension because of left heart disease requiring LVAD support, elevated DPG was associated with RV failure but not survival, while elevated PVR predicted mortality post LVAD implantation.
Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones
Legendre, Christophe, Gooden, Gerald , Huang, Yizhou Peter , Butry, Loren, Johnson, Kyle N., Martinez, Rae Anne , Pierobon, Mariaelena , Petricoin, Emanuel F. , O’Shaughnessy, Joyce , Osborne, C., Tapia, Coya, Buckley, David N. , Glen, Jennifer, Bernstein, Mark, Salhia, Bodour , Schroeder, Mark A. , Tew, Ben Yi , Triche, Timothy J. , Daniel, J. , Sarkaria, Jann N. , Toms, Steven A.

Mayo Clinic

Neuro-Oncology | August 8, 2019 | Volume: 22 | Issue: 1 | Pages: 70-83

10.1093/neuonc/noz137 | PMID 31433055 Get It

Abstract Background The dearth of relevant tumor models reflecting the heterogeneity of human central nervous system metastasis (CM) has hindered development of novel therapies. Methods We established 39 CM patient-derived xenograft (PDX) models representing the histological spectrum, and performed phenotypic and multi-omic characterization of PDXs and their original patient tumors. PDX clonal evolution was also reconstructed using allele-specific copy number and somatic variants. Results PDXs retained their metastatic potential, with flank-implanted PDXs forming spontaneous metastases in multiple organs, including brain, and CM subsequent to intracardiac injection. PDXs also retained the histological and molecular profiles of the original patient tumors, including retention of genomic aberrations and signaling pathways. Novel modes of clonal evolution involving rapid expansion by a minor clone were identified in 2 PDXs, including CM13, which was highly aggressive in vivo forming multiple spontaneous metastases, including to brain. These PDXs had little molecular resemblance to the patient donor tumor, including reversion to a copy number neutral genome, no shared nonsynonymous mutations, and no correlation by gene expression. Conclusions We generated a diverse and novel repertoire of PDXs that provides a new set of tools to enhance our knowledge of CM biology and improve preclinical testing. Furthermore, our study suggests that minor clone succession may confer tumor aggressiveness and potentiate brain metastasis.
“Get to Know Me” Board
Anderson, Ben D., Gajic, Ognjen

Mayo Clinic

Critical Care Explorations | August 1, 2019 | Volume: 1 | Issue: 8 | Pages: e0030

10.1097/cce.0000000000000030 | PMID 32166271 Get It

For best outcomes, clinicians in the ICU need to attend not only to the immediate clinical needs of the critically ill patient, but also to higher human needs including psychologic, social, and spiritual. Understanding your patient as another human being with her or his fears, desires, preferences, and accomplishments is obviously important in order to provide compassionate care and achieve goal concordant outcomes. In an ever-evolving technological ICU environment, this may not be an easy task. All too often, we focus on monitors, devices, electronic records, and ignore the human being. Patients labeled with a disability are particularly vulnerable. Recently, I had the privilege to participate in the care of a Mayo Clinic patient with a history of cerebral palsy. In the midst of a life-threatening emergency, by paying attention to the human touch, the ICU team learned the story of a truly remarkable person. The essay below summarizes the patient’s and physician’s perspectives.
Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device
Wood, David , Krajcer, Zvonimir , Sathananthan, Janarthanan , Strickman, Neil E., Metzger, Chris, Fearon, William F. , Aziz, Mark, Satler, Lowell F. , Waksman, Ron , Eng, Marvin H. , Heimansohn, David, Sampson, Andrew, Coady, Paul , Rodriguez, Roberto , Krishnaswamy, Amar , Lee, Jason T. , Ben‐Dor, Itsik , Moainie, Sina L. , Kodali, Susheel , Yadav, Pradeep , Kozak, Mark, Bacharach, J. Michael, Feldman, Ted , Nanjundappa, Aravinda , Bersin, Robert M., Potluri, Srinivasa , Barker, Colin M. , Bernardo, Nelson L. , Lumsden, Alan B. , Dake, Michael D. , Brown, David L. , Maor, Nathaniel, Nardone, Samuel, Webb, John G. , Investigators, on behalf of the SAFE MANTA Study, Kapadia, Samir , Greenbaum, Adam B. , Szerlip, Molly , Chhatriwalla, Adnan K , O’Neill, Brian Patrick , Guerrero, Mayra , Zhang, Ming , Barleben, Andrew R. , Campbell, John , Cohen, David Jonathan , Lauck, Sandra , O’Neill, William W. , Investigators, on behalf of the SAFE MANTA Study

Mayo Clinic

Circulation: Cardiovascular Interventions | July 12, 2019 | Volume: 12 | Issue: 7 | Pages: No page available

10.1161/circinterventions.119.007258 | PMID 31296082 Get It

Background: Open surgical closure and small-bore suture-based preclosure devices have limitations when used for transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, or percutaneous thoracic endovascular aortic aneurysm repair. The MANTA vascular closure device is a novel collagen-based technology designed to close large bore arteriotomies created by devices with an outer diameter ranging from 12F to 25F. In this study, we determined the safety and effectiveness of the MANTA vascular closure device. Methods and Results: A prospective, single arm, multicenter investigation in patients undergoing transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, or thoracic endovascular aortic aneurysm repair at 20 sites in North America. The primary outcome was time to hemostasis. The primary safety outcomes were accessed site-related vascular injury or bleeding complications. A total of 341 patients, 78 roll-in, and 263 in the primary analysis cohort, were entered in the study between November 2016 and September 2017. For the primary analysis cohort, transcatheter aortic valve replacement was performed in 210 (79.8%), and percutaneous endovascular abdominal aortic aneurysm repair or thoracic endovascular aortic aneurysm repair was performed in 53 (20.2%). The 14F MANTA was used in 42 cases (16%), and the 18F was used in 221 cases(84%). The mean effective sheath outer diameter was 22F (7.3 mm). The mean time to hemostasis was 65±157 seconds with a median time to hemostasis of 24 seconds. Technical success was achieved in 257 (97.7%) patients, and a single device was deployed in 262 (99.6%) of cases. Valve Academic Research Consortium-2 major vascular complications occurred in 11 (4.2%) cases: 4 received a covered stent (1.5%), 3 had access site bleeding (1.1%), 2 underwent surgical repair (0.8%), and 2 underwent balloon inflation (0.8%). Conclusions: In a selected population, this study demonstrated that the MANTA percutaneous vascular closure device can safely and effectively close large bore arteriotomies created by current generation transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, and thoracic endovascular aortic aneurysm repair devices. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02908880.